WASF3
Wiskott-Aldrich syndrome protein family member 3
Protein Summary
Downstream effector molecules involved in the transmission of signals from tyrosine kinase receptors and small GTPases to the actin cytoskeleton. Plays a role in the regulation of cell morphology and cytoskeletal organization. Required in the control of cell shape. This gene encodes a member of the Wiskott-Aldrich syndrome protein family. The gene product is a protein that forms a multiprotein complex that links receptor kinases and actin. Binding to actin occurs through a C-terminal verprolin homology domain in all family members. The multiprotein complex serves to tranduce signals that involve changes in cell shape, motility or function. A pseudogene of this gene have been defined on chromosome 6. Alternative splicing results in multiple transcript variants [provided by RefSeq, May 2014]
- ENST00000335327
- ENSP00000335055
- ENSG00000132970
- ENST00000361042
- ENSP00000354325
- KIAA0900
- SCAR3
- WAVE3
- SCAR3
- WAVE3
- Brush-1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
disease perturbation | 0.79 | ||
tissue sample | 0.76 | ||
transcription factor | 0.67 | ||
kinase perturbation | 0.66 | ||
microRNA | 0.62 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 68.6 (req: < 5)
Gene RIFs: 33 (req: <= 3)
Antibodies: 196 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 68.6 (req: >= 5)
Gene RIFs: 33 (req: > 3)
Antibodies: 196 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 9
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0